The Safety and Efficacy of Ruxolitinib in an Infant With Familial Hemophagocytic Syndrome Type 3: A Bridging Therapy Toward Hematopoietic Cell Transplantation and Treatment of Post‐Transplant Complications, Including Sinusoidal Obstruction Syndrome

Kazuki Takahashi; Shinsuke Hirabayashi; Masahiro Ueki; Masataka Hasegawa; Hiroki Ohata; Shunichiro Takezaki; Yukayo Terashita; Yuko Cho; Atsushi Manabe

doi:10.1002/pbc.32073

journal article Sep 24, 2025

The Safety and Efficacy of Ruxolitinib in an Infant With Familial Hemophagocytic Syndrome Type 3: A Bridging Therapy Toward Hematopoietic Cell Transplantation and Treatment of Post‐Transplant Complications, Including Sinusoidal Obstruction Syndrome

Kazuki Takahashi

Shinsuke Hirabayashi

Masahiro Ueki

Masataka Hasegawa Hiroki Ohata Shunichiro Takezaki Yukayo Terashita

Yuko Cho Atsushi Manabe

Pediatric Blood & Cancer Vol. 72 No. 12 · Wiley

View at Publisher Save 10.1002/pbc.32073

Topics

No keywords indexed for this article. Browse by subject →

References

28

[1]

Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation

J.-I. Henter

Blood 10.1182/blood-2002-01-0172

[2]

10.1111/pai.13323

[3]

10.1182/blood-2005-05-1819

[4]

10.1186/1750‐1172‐2‐35

[5]

10.1016/j.cellimm.2011.01.008

[6]

Nash R. A. "Phase 3 Study Comparing Methotrexate and Tacrolimus With Methotrexate and Cyclosporine for Prophylaxis of Acute Graft‐Versus‐Host Disease After Marrow Transplantation From Unrelated Donors" Blood (2000)

[7]

10.1016/j.bbmt.2010.01.010

[8]

10.3324/haematol.2016.149294

[9]

10.1016/j.leukres.2013.06.016

[10]

10.1186/s13045-014-0059-3

[11]

10.1038/bmt.2013.107

[12]

Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults

Sonata Jodele, Stella M. Davies, Adam Lane et al.

Blood 10.1182/blood-2014-03-564997

[13]

10.1016/j.blre.2014.11.001

[14]

10.1002/hep.23533

[15]

10.3390/cancers15030680

[16]

10.3389/fimmu.2022.954268

[17]

Liang H. "Replacement of Calcineurin Inhibitor With Ruxolitinib as GVHD Prophylaxis During Patients With Vascular Endothelial Syndromes After Allogeneic Stem Cell Transplantation" Clinical Oncology (2022)

[18]

10.1038/bmt.2016.130

[19]

10.1016/j.bbmt.2018.05.025

[20]

Jodele S. "Complement Blockade for TA‐TMA: Lessons Learned From a Large Pediatric Cohort Treated With Eculizumab" Blood (2020)

[21]

10.1182/blood-2011-06-356261

[22]

Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3

Daiki Niizato, Takeshi Isoda, Noriko Mitsuiki et al.

Frontiers in Immunology 10.3389/fimmu.2022.977463

[23]

10.3324/haematol.2023.283478

[24]

10.1016/j.bbmt.2009.08.024

[25]

10.1159/000028359

[26]

10.1016/j.bbmt.2007.03.012

[27]

10.1177/1076029615598221

[28]

10.1182/blood‐2005‐12‐4851

Metrics

1

Citations

28

References

Details

Published: Sep 24, 2025
Vol/Issue: 72(12)
License: View

Authors

K

Kazuki Takahashi